Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Ability to understand and voluntarily sign an informed consent form
Age > 18 years at the time of signing the informed consent form
Histological confirmation of advanced stage, primary or metastatic colorectal carcinoma

Prior therapy (Group 1, irinotecan naive):

No more than one regimen for metastatic disease
No more than two regimens overall; one for neoadjuvant/adjuvant and one for metastatic/advanced disease

Prior therapy (Group 2, irinotecan refractory):

Disease progression on or within 3 months after prior irinotecan-containing regimen
CPX-1 treatment must start within 6 months after documentation of disease progression on irinotecan (other therapies are permitted after irinotecan and before study entry)
Must have measurable disease as defined by RECIST
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Able to adhere to the study visit schedule and other protocol requirements
Life expectancy of at least 24 weeks

Laboratory values fulfilling the following:

Absolute neutrophil count (ANC) >1500 cells/mm3 (1.5 x 109/L)
Platelet count > 100,000/mm3 (100 x 109/L)
Serum creatinine <1.5 x upper limits of normal (ULN)
Serum SGOT/AST and SGPT/ALT <3 x upper limits of normal (ULN) (<5 times ULN if caused by liver metastases)
Serum total bilirubin < 1.25 x upper limits of normal (<2 times ULN if caused by liver metastases)
All men and women must agree to practice effective contraception during the study period and for three months afterward if not otherwise documented to be infertile.
Prior radiation therapy must be completed at least 4 weeks prior to enrollment and the patient recovered from any toxicity related to the radiation therapy.

Exclusion Criteria:

Prior treatment with irinotecan or an irinotecan-containing regimen (Group 1 only)
Intolerant of an irinotecan-containing regimen (Group 2 only)
Without documented evidence of irinotecan-refractoriness (Group 2 only)
Chemotherapy or investigational anticancer therapeutic drugs in the four weeks prior to study entry.
Hypersensitivity to irinotecan, floxuridine or liposomal products.
History of Wilson's disease or other copper-related disorder.
Clinically significant cardiac disease (New York Heart Association Class III or IV).
Severe debilitating pulmonary disease.
Active infection requiring continuing intravenous antibiotic treatment; recent infections must have resolved at least 5 days
Severe or active enteropathy or recurrent onset of diarrhea, defined as an excess of 2 to 3 stools above the normal daily rate within the past four weeks.
Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form.
Pregnant or lactating women. Continued use of a drug or other product known to induce or inhibit CYP3A4. ---Patients must discontinue these products for at least 2 week prior to enrollment.